Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsOrchid pharma

    Orchid Pharma

    Jump to

    • Orchid Pharma Consolidated September 2025 Net Sales at Rs 193.52 crore, down 13.1% Y-o-Y

    • Orchid Pharma Standalone September 2025 Net Sales at Rs 193.52 crore, down 13.1% Y-o-Y

    • Orchid Pharma Standalone June 2025 Net Sales at Rs 172.93 crore, down 29.25% Y-o-Y

    • Orchid Pharma Standalone March 2025 Net Sales at Rs 237.48 crore, up 9.39% Y-o-Y

    • Stocks On Radar: HFCL, Waaree Energies, IREDA, Orchid Pharma in focus on 20 February

      Join us for the latest stock market update where we cover the key stocks making headlines today. HFCL leads with a groundbreaking agreement under BharatNet Phase-III, while Waaree Energies secures a major solar module supply order. Plus, insights on IREDA and Tata Technologies' new trading contracts, Cyient's executive appointment, Patanjali Foods' legal victory, and Orchid Pharma's recent FDA inspection. Stay informed with our comprehensive overview of today's trading focuses!

    • Orchid Pharma shares gain despite USFDA issues seven minor observations

      Orchid Pharma Share Price | The inspection, which commenced on 10 February 2025 and concluded on 18 February 2025, resulted in seven minor observations, none of which pertain to the data integrity of the facility.

    • Stocks to Watch Today: HFCL, Waaree Energies, IREDA, Tata Technologies, Sundaram Clayton, Orchid Pharma in focus on 20 February

      Stocks To Watch, Feb 20: Stocks like RITES, Patanjali Foods, National Fertilizers, Cyient, Awfis Space Solutions, IRIS Business Services, Torrent Power, Sundaram Clayton, Flomic Global Logistics, BSE, and Windlas Biotech will be in focus on February 20.

    • Orchid Pharma Standalone December 2024 Net Sales at Rs 217.34 crore, down 1.47% Y-o-Y

    • Trade Spotlight: How should you trade Mastek, City Union Bank, Ceat, Jubilant Ingrevia, JTEKT India, and others on Monday?

      Given the improved sentiment after the counter-attack by bulls, the benchmark indices are expected to extend their upward rally amid possible consolidation. Below are some trading ideas for the near term.

    • Orchid Pharma Consolidated September 2024 Net Sales at Rs 222.70 crore, up 12.05% Y-o-Y

    • Orchid Pharma Standalone September 2024 Net Sales at Rs 222.70 crore, up 12.05% Y-o-Y

    • Orchid Pharma Consolidated June 2024 Net Sales at Rs 244.41 crore, up 33.61% Y-o-Y

    • Orchid Pharma Standalone June 2024 Net Sales at Rs 244.41 crore, up 33.61% Y-o-Y

    • Stock Radar: Vodafone Idea, Orchid Pharma, JSW Steel, FirstCry, Hindustan Copper, Power Grid in focus on Tuesday

      NMDC, Housing & Urban Development Corporation, 63 Moons Technologies, Indian Railway Finance Corporation, Camlin Fine Sciences, Kotak Mahindra Bank, Wipro, and Aditya Birla Sun Life AMC will also be in focus on Tuesday.

    • Trade Spotlight: How should you trade Orchid Pharma, India Glycols, Inox Green Energy, NBCC, and others on Tuesday?

      A close above 24,500 could drive the Nifty 50 towards the 24,700-24,800 zone, but if it stays below this level, consolidation and range-bound trading may continue with 24,200 as support. Here are some trading ideas for the near term.

    • Stock Radar: Neogen Chemicals, Godrej Properties, Zydus Life, JSW Energy, HFCL in focus on Monday

      HDFC Life Insurance Company, Orchid Pharma, Cipla, HFCL, Stanley Lifestyles, and Samhi Hotels will also be in focus on Monday.

    • Orchid Pharma Consolidated March 2024 Net Sales at Rs 217.10 crore, up 3.43% Y-o-Y

    • Orchid Pharma Standalone March 2024 Net Sales at Rs 217.10 crore, up 3.43% Y-o-Y

    • Stock Radar: IndiGo, HCL Tech, Honasa Consumer, Fortis Healthcare, Zaggle Prepaid in focus on Friday

      NTPC, Hindalco, Bosch, Ashok Leyland, Hindustan Copper, Glenmark Pharma, Aegis Logistics, Manappuram Finance, Suzlon Energy, Torrent Pharmaceuticals, and United Spirits will announce their March quarter earnings on May 24.

    • Orchid Pharma Consolidated December 2023 Net Sales at Rs 220.59 crore, up 38.08% Y-o-Y

    • Orchid Pharma Standalone December 2023 Net Sales at Rs 220.59 crore, up 38.08% Y-o-Y

    • Orchid Pharma stocks gain 2% as promoter sells 2.56% stake

      Orchid Pharma's Promoter Dhanuka Laboratories sold 13 lakh equity shares or a 2.56 percent stake, in the company via open market transaction at an average price of Rs 571.28 per share.

    • Orchid Pharma Consolidated September 2023 Net Sales at Rs 198.76 crore, up 20.28% Y-o-Y

    • Orchid Pharma Standalone September 2023 Net Sales at Rs 198.76 crore, up 20.28% Y-o-Y

    • Orchid Pharma Consolidated June 2023 Net Sales at Rs 182.92 crore, up 39.65% Y-o-Y

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347